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The foremost aim of the current research was to prolong and sustain the release of erythromycin (ERY) 
by preparing a solid lipid nanoparticles (SLNs)-based gel formulation for the safe and effective treatment 
of acne. ERY-loaded SLNs were developed, and various process variables were optimized with respect 
to particle size, zeta potential, and entrapment efficiency using the Taguchi model. The average particle 
size, PDI, zeta potential, drug entrapment efficiency, and drug loading of optimized SLN (F4) were found 
to be 176.2±1.82 nm, 0.275±0.011, -34.0±0.84, 73.56%, and 69.74% respectively. The optimized SLN 
(F4) was successfully incorporated into the carbopol-based hydrogel. The in vitro release of ERY from 
the SLN gel and plain gel were compared and found to be 90.94% and 87.94% respectively. In vitro 
study of ERY-loaded SLN gel showed sustained delivery of drug from formulation thus enhancing the 
antimicrobial activity after 30 hours when compared to ERY plain gel.
Keywords: Erythromycin. Solid lipid nanoparticles. Nanogel. Taguchi model. Characterization. Diffusion 
disc.
INTRODUCTION
Solid lipid nanoparticles (SLNs) offer an attractive 
means of drug delivery, particularly for poorly water-
soluble drugs. They blend the advantages of polymeric 
nanoparticles (Nadkar, Lokhande, 2010), emulsions, and 
liposomes (Loxley, 2009; Mishra, Patel, Tiwari, 2010). 
SLNs consist of the drug entrapped in a biocompatible 
lipid core and surfactant in the outer shell, offering a good 
alternative to polymeric systems (Ekambaram, Sathali, 
Priyanka, 2012) in terms of lower toxicity (Muller, 
Mader, Gohla, 2000). Moreover, the production process 
can be modulated for desired drug release, protection 
of drug degradation, and avoidance of organic solvents. 
The aforementioned advantages make SLNs a promising 
carrier system for optimal drug delivery (Helgason et al., 
2009). ERY is a safe and effective agent for the treatment 
of acne. Furthermore, dibenzoyl peroxide’s lipophilic 
nature enhances transport through sebaceous glands, with 
maximum penetration through acne follicles. ERY can be 
bonded with the SLN surface to facilitate drug targeting 
of the skin strata and increase the efficiency of the acne 
remedy (Mehnert, Mader, 2001).
Topical ERY is used for the treatment of inflammatory 
acne vulgaris that occurs due to activity against propioni 
bacterium acne (Manjunath, Enkateswarlu, 2004). It is 
slightly soluble in water and freely soluble in methanol. 
ERY base and triamcinolone acetonide are examples 
of topical drugs with poor dermal localization due to 
lipophilicity. SLNs could be suitable carriers for these 
drugs with a potential impact on their dissolution.
The Taguchi model has been successfully used 
for the optimization of process variables. The design 
of the experiments aims to reduce the experimental 
runs required for optimization. The Taguchi model 
design is based on a special set of orthogonal arrays to 
standardize fractional factorial designs. This approach 
reduces the size of the factorial design. An orthogonal 
array implies that the design is well-adjusted such that 
the factor levels are weighed equally. Each factor can be 
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evaluated independently of the other factors. This allows 
the assessment of the effect of one factor without the 
interference of the effects of other factors (Taguchi, 1987).
The purpose of this study to develop ERY-loaded 
SLNs-based gel with the potential to sustain and delay the 
release of the drug. The developed gel may be suitable for 
the treatment of acne.
MATERIAL AND METHODS
Material
Glyceryl monostearate, Polaxomer 188, stearic 
acid, and Comparitol were obtained from HiMedia Lab, 
Mumbai, India. Lecithin was obtained from Spectrum 
Chemicals and erythromycine from Yarrow Chemicals, 
Mumbai, India. All the other reagents and solvents used 
were of analytical reagent grade.
Formulation and optimization of SLNs
Selection of method for preparation of SLNs
Three different methods were used for the preparation 
of ERY-loaded SLNs.
Microemulsion Technique
The lipid is melted, and a mixture of water, surfactant, 
and co-surfactant(s) was heated at the same temperature as 
the lipid. It was then added under mild stirring (1000 rpm) 
to the melted lipid. A transparent, thermodynamically 
stable system was formed, since the compounds were 
mixed in the correct ratio. This microemulsion was then 
dispersed in a cold aqueous medium (2–3 °C) under mild 
mechanical mixing ensuring that the small size of the 
particle is due to the precipitation and not mechanically 
induced by a stirring process (Surender, Deepika, 2016).
Solvent Emulsification/Evaporation Technique
The lipid was dissolved in a water-miscible organic 
solvent (methanol and chloroform, 1:1) and the drug was 
dispersed in the lipid solution. It was then emulsified 
in an aqueous phase containing the surfactant and the 
co-surfactant. Upon evaporation of the solvent in a Rota 
evaporator, a nanoparticle dispersion was formed by the 
precipitation of the lipid in the aqueous phase (Ahlin, 
Kristl, Kobar, 1998).
Solvent Emulsification Diffusion Technique
Different amounts of drugs and lipids were taken 
– each dissolved in a 2 mL mixture of methanol and 
chlorofonn (1:1) separately (as internal oil phase). 
Powdered ERY (50 mg) was dispersed in the above 
solution and sonicated for 2 minutes. The resulting 
dispersion was poured into a solution containing 1.5% 
(w/v) aqueous surfactant solution (PluronicF-68) and 
homogenized for 30 minutes at 4000 rpm to form an o/w 
emulsion. After homogenization, the emulsion was poured 
into ice-cold water up to a volume of 50 ml and stirred 
for 3 hours to diffuse the organic solvent into external 
aqueous phase water. The dispersion was then centrifuged 
at 12000 rpm for 15 minutes (Sartorius FI8 K) to separate 
the solid lipid material containing the drug. This was then 
re-dispersed in a 1.5% aqueous surfactant (Pluronic F-68) 
solution and sonicated for 10 minutes (Surender, Deepika, 
2016).
Optimization of formulation component and 
process variables
Screening of lipids for SLNs
A constant amount of drug (50 mg) was weighed and 
dispersed into the lipid solution in different ratios ranging 
from 1:1 to 1:10 of lipids, and the rest of the parameters 
were kept constant. The surfactant concentration was 
found to be 1% w/w. It was then homogenized for 
30 minutes with a stirring time for 3 hours and sonicated 
for 5 minutes.
Optimization of drug lipid loading ratio
A constant amount of drug (50 mg) was weighed 
and dispersed into lipid in different ratios ranging from 
1:1 to1:5 of lipids and the rest of the parameters were kept 
constant. The surfactant concentration was 1% w/w. It 
was homogenized for 30 minutes with a stirring time for 
3 hours and then sonicated for 5 minutes.
Optimization of surfactant concentration
On the basis of the reported literature, the 
concentration of surfactant was optimized for a drug lipid 
ratio of 1:2. The ratios used for the formulation were 0.5%, 
1%, 1.5%, and 2%. The surfactant was added at the time 
of emulsification, and the concentration of the surfactant 
was optimized regarding the particle size and aggregation 
after 24 hours.
Optimization of stirring time
During the process of stirring, organic solvents 
diffuse into the aqueous phase, leading to the synthesis of 
SLNs. The speed and the time of stirring may influence 
the particle size as well as the drug entrapment. In the 
present study, the stirring speed was kept constant at 
3000 rpm (calibrated by thread method), and the time of 
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stirring was optimized. Three points of time were used for 
the optimization – 30, 45, and 60 minutes – at a constant 
surfactant concentration of 2%, a drug: lipid ratio of 1:2, 
and a sonication time of 4 minutes.
Optimization of probe sonication
The probe sonicator (Bandelin Sonoplus, Biomate 
India) was used to optimize the sonication time viz 5, 10, 
15, and 20 minutes with the following parameters 5 × 10 
cycle and 50% power.
Design of experiments by the Taguchi model
This involves the factorial design for optimization 
of process variables (Nazzal, Khan, 2002).On the basis 
of the literature reported, the aforementioned series of 
experiments were performed to identify the controlling 
factor and the noise factor. There are various factors that 
seem to affect the formulation. An experimental design 
is a statistical technique used to simultaneously analyze 
the influence of multiple factors on the properties of the 
system being studied. The purpose of an experimental 
design is to plan and conduct experiments in order to 
extract the maximum amount of information from the 
collected data in a minimal number of experimental runs. 
Factorial design, based on the response surface method, 
is applied to design formulations. However, an increase 
in the number of factors significantly increases the 
number of experiments that need to be carried out. The 
Taguchi approach proposes a special set of orthogonal 
arrays to standardize the fractional factorial design. This 
approach reduces the size of the factorial design, and a 
study can be performed with 9 sets of experiments for 
a three-level, four-factor (34) design of experiments. 
The codes for all four variables at three different levels 
are illustrated in Table VII in the results and discussion 
section.
Characterization of SLNs
Measurement particle size, zeta potential, and size 
distribution
SLNs dispersions were diluted 50 times with the 
double distilled water for size determination and zeta 
potential measurement. Higher value of zeta potential 
may lead to disaggregation of particles in the absence 
of other complicating factors such as steric stabilizers 
or hydrophilic surface appendages. Zeta potential 
measurements allow predictions regarding the storage 
stability of colloidal dispersions (Yassin et al., 2010; 
Anwer et al., 2016a; Anwer et al., 2016b).
In vitro drug release studies from SLNs
In vitro release studies were performed in pH 6.4 
phosphate buffer using dialysis membrane (Mol. wt. 
12000–14000 Dalton), and 5 mL of suspension was placed 
inside the dialysis tube, following which it was dipped the 
filled tube in buffer medium. The rpm of magnetic bead was 
100 and the temperature was 37 °C. At time intervals 0, 0.25, 
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 hours, 1 mL aliquots 
were withdrawn, diluted suitably with fresh buffer solution, 
and analyzed for the drug content spectrophotometrically 
at 483.5 nm (Bhadra, Prajapati, Bhadra, 2016). The in vitro 
drug release was performed in triplicate. The concentration 
of ERY in test samples was calculated using a regression 
equation of the calibration curve.
Development of optimized SLN-loaded gel
Hydrogel base were prepared by carbopol 940. 
Carbopol resin were soaked in double distilled water (10% 
Glycerin) for 12 hours and then dispersed by agitating at 
approximately 1000 rpm with aid of mechanical stirrer 
for 10 minutes to get a smooth dispersion. Stirring was 
stopped and dispersion was allowed to stand so that any 
entrained air could escape. At this stage, optimized ERY-
loaded SLN was incorporated into gel with continuous 
stirring for 10 minutes. Any entrapped air in the gel was 
allowed to escape by allowing the gels to stand overnight 
(Bisht et al., 2017).
Evaluation of hydrogel
The developed gel was evaluated for their clarity, 
pH, viscosity, spreadability, extrudability, occlusion effect, 
and in vitro drug release (Bisht et al., 2017).
Clarity
The clarity of developed gel formulation was 
determined by visual inspection under black and white 
background and it was graded as follows;
Turbid: +, clear: ++, very clear (glassy): +++.
pH
2.5 gm of gel was accurately weighed and dispersed 
in 25 ml of distilled water. The pH of dispersion was 
measured by digital pH meter (Systronic pH system 362).
Homogeneity
All developed gels were tested for homogeneity 
by visual inspection after the gels have been set in the 
container for their appearance and presence of any 
aggregate.
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Spreadability
It was determined by wooden block and slide 
apparatus invented by Multimer et al.(1956). For the 
determination of spreadability, l gm of sample was applied 
in between two glass slide and was compressed to uniform 
thickness by placing some weight for 5 minutes. Weight 
(50gm) as added to pan. The time required to separate 
the two slides, i.e. the time in which the upper glass 
slide moves over the lower plates was taken as measure 
of spreadability (S).Time (T) taken to separate the slide 
completely from each other Viscosity measurement. 
The value of spreadability indicates that the gel is easily 
spreadable by small amount of shear.
Spreadability was calculated by using the formula:
S = ML/T
where S = Spreadability; M = Weight tide to upper slide; 
L = Length moved on the glass slide; T = Time.
Extrudability
The extrudability test was carried out by using 
Pfizer tester, l0gm of gel was filled in aluminum tube. 
The plunger was adjusted to hold the tube properly. The 
pressure of l Kg/gm2 was applied for 30 sec. The quantity 
of gel extruded was weighed. The procedure was repeated 
at three equidistance places of the tube. Test was carried 
out in triplicates.
Viscosity
Viscosity of the gels was determined using a 
Brookfield viscometer, by using small sample adapter 
having spindle number SC4/13R (Middleboro, MA, USA). 
The gel was subjected to torque ranging from 10 to 100%. 
The viscosity of various formulation ERY hydrogel was 
measured using a Brookfield viscometer.
In vitro drug release from SLN gel
In vitro release studies were performed in phosphate 
buffer (pH 6.4) using dialysis membrane (Mol wt. 
12000-14000 Dalton), and 0.5 gm of ERY-loaded plain 
gel as well as ERY SLN-loaded gel were placed inside 
the dialysis bag and dipped in a tube containing buffer 
medium. The tubes were placed in the biological shaker 
after setting 100 rpm and temperature 37 °C. Aliquots 
(1 mL) were withdrawn at time intervals (0.5, 1, 2, 3, 4, 5, 
6, 7, 8, 10, 12, and 24) and replaced by an equal volume 
of fresh dissolution medium. The samples were analyzed 
spectrophotometrically in triplicate at 483.5 nm after 
suitable dilution (Bhadra, Prajapati, Bhadra, 2016). The in 
vitro release data was fitted according to different kinetic 
models to analyze the release behavior from SLN-loaded 
gel (Bisht et al., 2017).
In vitro antimicrobial activity: Disk diffusion 
method
Disk diffusion refers to the diffusion of an 
antimicrobial agent of a specified concentration from 
disks, tablets, or strips into a solid culture medium that 
has been seeded with the selected inoculum isolated in a 
pure culture. Disk diffusion is based on the determination 
of an inhibition zone that is proportional to the bacterial 
susceptibility and the antimicrobial present in the disk. 
The diffusion of the antimicrobial agent into the seeded 
culture media results in a gradient of the antimicrobial 
agent. When the concentration of the antimicrobial agent 
becomes so diluted it can no longer inhibit the growth of the 
test bacterium, the zone of inhibition is demarcated. The 
diameter of this zone of inhibition around the antimicrobial 
disk is related to minimum inhibitory concentration (MIC) 
for that particular bacterium/antimicrobial combination. 
The zone of inhibition correlates inversely with the MIC 
of the test bacterium. Generally, the larger the zone of 
inhibition, the lower the concentration of antimicrobial 
agent required to inhibit the growth of the organisms. 
However, this depends on the concentration of antibiotic 
in the disk as well as its diffusibility.
The in vitro antibacterial activities of plain gel and 
SLN-loaded gel were performed against S. aureus by disc 
diffusion method. Under aseptic conditions, empty sterile 
discs were impregnated with 50 mg of ERY SLN-loaded 
gel as well as ERY plain gel and placed on the surface of 
the agar using sterile forceps. All petri dishes containing 
the microorganisms were sealed and incubated for 48 
hours in a temperature of 37°C. After the incubation 
period, the diameter of the inhibition zones was observed 
where clear zones were seen on the agar and measured 
using a ruler to the nearest millimeter readings. The test 
was performed in triplicates, and mean values of the 
diameters of the inhibition zones were calculated for both 
samples (Balouiri, Sadiki, Ibnsouda, 2016).
RESULTS AND DISCUSSION
Formulation and optimization of SLN
Selection of preparation of method
The microemulsion technique was selected as 
the method of choice in the formulation of solid lipid 
nanoparticles, because it showed better results in terms 
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of particle size, particle shape, drug entrapment etc. as 
compared to the other methods, as seen in Table I. The 
versatility and flexibility of this method allows for the 
use of different lipids and drug candidates. In the present 
study, the lipid glyceryl monostearate was used for the 
preparation of ERY-loaded SLNs.
Optimization of formulation component
Screening of lipids for SLNs
Three lipids – stearic acid, glycerol monostreate, and 
Comparitol 888 – were used for the formation of SLNs. 
A drastic increase in the particle size and decrease in drug 
entrapment was observed with the use of Comparitol 
888 and stearic acid. Among these lipids, glyceryl 
monostearate was selected for the development of SLNs 
as mentioned in Table II. GMS had the particle size within 
the nanoparticle range and the demonstrated maximum 
drug entrapment.
Optimization of drug lipid loading ratio
A drastic increase in the particle size and decrease 
in the drug entrapment was observed when the drug: 
lipid ratio was increased from 1:1 to 1:5 w/w. The results 
indicate that the optimal drug lipid ratio is 1:2w/w, as 
depicted in Table III. The increase in particle size and 
decrease in drug entrapment was probably caused by the 
increase in lipid quantity, which resulted in drug expulsion 
due to the crystalline structure of lipid.
Optimization of surfactant concentration
The concentration of the surfactant was optimized in 
order to obtain the smallest possible SLNs with maximum 
percentage of drug entrapment. The optimized one had 
0.5% concentration of surfactant, as it lead to the smallest 
particle size, zeta potential within range, and it did not 
cause aggregation after 24 hours, as depicted in Table IV.
Optimization of stirring time
During stirring, the organic solvent diffused into 
the aqueous phase, leading to the synthesis of SLNs. The 
speed and time of stirring may influence the particle size as 
well as the drug entrapment. Upon increasing the stirring 
time from 30 to 60 minutes, a decrease in particle size from 
528 to 176 nm and an increase in entrapment i.e. 78.59% 
was observed (Table V).
Optimization of Sonication time
The sonication time was optimized by using the 
Bandlin Sonoplus by Biomate India, and 20 minutes of 
sonication was found to be the optimum time to reduce 
the particle size (Table VI).
TABLE I - Comparison between different methods used for the 
preparation of SLNs






















TABLE II - Screening of lipids for SLNs






Stearic Acid 1391 ± 4.76 0.569 ± 0.06 48.24 ± 1.39
GMS 176.2 ± 0.48 0.275 ± 0.05 73.56 ± 0.28
Comparitol 
888 ATO
380.8 ± 1.67 0.412 ± 0.02 57.29 ± 0.81
TABLE III - Optimization of drug lipid ratio
Drug Lipid Ratio Particle Size (in nm)
Drug Entrapment 
(%)
1:1 159 ± 0.91 44.2 ± 0.36
1:2 176 ± 0.86 78.1 ± 0.74
1:3 476 ± 1.75 55.3 ± 1.03
1:4 508 ± 2.56 22.4 ± 0.55
1:5 719 ± 3.21 34.5 ± 0.87









0.5% 176 ± 1.87 24.42 ± 0.95 -
1.0% 213 ± 1.78 25.26 ± 1.02 -
1.5% 224 ± 2.12 24.12 ± 0.59 +
2.0% 278 ± 1.27 24.38 ± 1.01 +
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Design of experiment by Taguchi model
The Taguchi model was used for simultaneous 
optimization of all variables used in the design of various 
nine formulations (F1–F9). All these variables were used at 
three different levels. The results in terms of particle size, 
polydispersity index, zeta potential, and drug entrapment 
efficiency are tabulated in Table VIII. In Formulation F1 
lump formation occurred after 24 hours, therefore, the 
batch was discarded. F4 led to the smallest particle size 
with the highest drug loading capacity, therefore this batch 
was used as the optimized formulation. The codes for all 
four variables at three different levels were shown in the 
Table VII. On the basis of particle size, batch 4 is taken as 
optimized, hence the optimized parameter was found to 
be A2B1C2D3 as shown in above mentioned Table VII.
Measurement particle size, zeta potential, and size 
distribution
The particle size of formulation was found in 
the range of 176.2 to 374 nm, as shown in Table VIII. 
Formulation factors like lipid amount and poloxamer 
188 concentration were found to influence the particle 
size of the formulation significantly. Zeta potential (ZP) 
is the charge on a particle surface, and it is the inherent 
property of a particle. ZP plays a major role in the stability 
of multi-particulate liquid systems. It does not allow the 
particles to come in contact with each other and prevents 
aggregation thereby stabilizing the system. The ZP of 
glycerin monostreate-based SLN was found to be -34.0 
indicating a stable formulation. PDI measures the particles 
size distribution in a system. This indicates the variation/
dispersion in particle size in SLN dispersion. The PDI 
values of the developed SLNs were found to be less than 
1, confirming monodisperse particles (Table VIII).
In vitro drug release studies from SLNs
As seen in Figure 2, F4 was selected as the 
optimized formulation. It was clear from all the 
formulations that there was an initial burst release 
ranging from 5.879% (F2) to15.773% (F7). This was due 
to surface-absorbed drug on SLNs, which was followed 
by a sustained release, varying from 73.18% (F8) to 
92.90% (F4) as shown in Figure 2. This is due to the 
drug slowly diffusing through the lipid core. Thus, the 
formulation F4 was optimized as it released 93% of the 
drug in 24 hours. It was revealed from the results that 
ERY-loaded SLNs showed a slow release at pH 6.4 with 
a sustained pattern of release.
Evaluation of ERY SLN-loaded gel formulation
ERY SLN gel prepared with Carbopol 940 was 
evaluated for crucial parameters as listed in Table VIII. 
The gel demonstrated the desired homogeneity and 
viscosity as well as high spreadability and extrudability for 
the formulation. The rheological behavior of gel systems 
was studied. In a gel system, the consistency depends on 
the ratio of solid fraction, which produces the structure of 
the liquid fraction. The viscosity of ERY-loaded SLNs gel 
was found to be 9563±7.48 centipoises. The gel was found 
to be uniform with pourable viscosity.
TABLE V - Optimization of Stirring Time
Time (min.) Particle Size (nm) Drug Entrapment (%)
30 528 ± 3.29 59.94 ± 0.50
45 213 ± 2.25 64.73 ± 0.18
60 176 ± 1.73 78.59 ± 0.12
TABLE VI - Showing Optimization of Probe Sonication
Sonication time 
(min) Particle size (nm) Drug Loading
5 217.6 ± 1.78 59.94 ± 0.54
10 204.5 ± 2.16 63.23 ± 0.76
15 189.8 ± 1.09 68.92 ± 0.52
20 188.9 ± 1.42 72.79 ± 0.12




Drug to lipid ratio A1 (1:1) A2 (1:2) A3 (1:3)
Conc. of Surfactants B1 (0.5%) B2 (1%) B3 (1.5%)
Stirring time (min.) C1 (30 min) C2 (45 min) C3 (60 min)
Sonication time (min.) D1 (10 min) D2 (15 min) D3 (20 min)
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In vitro release profile of gel
The in vitro release profile (Figure 3) of ERY plain 
gel (2%w/w) and ERY SLN-loaded gel (2%w/w) are seen 
in Figure 3. The percentage of cumulative drug release 
of plain gel and ERY-loaded SLN gel were found to be 
90.94% and 87.94% respectively after 24 hours. The 
release of ERY from SLN-loaded gel was found to be low 
as compared to plain gel. SLN gel showed slower and more 
sustained release as compared to ERY plain gel.
The rate of the release of ERY SLN-loaded gel was 
studied by using various models. In the case of lipophilic 
matrices, swelling and erosion of polymers occurs 
simultaneously, and both contribute to the overall drug 
release rate. It was documented earlier that the drug release 
from lipophilic matrices shows a typical time-dependent 
TABLE VIII - Codes for four variables at three different levels
Codes
Parameters Particle Size 
(nm) PDI ZP (mV) DL (%) DE (%)A B C D
F1 1 1 1 1 Lump Formation
F2 1 2 2 2 256.6 ± 2.41  0.314 ± 0.008 24.26 ± 0.83 34.29 31.29
F3 1 3 3 3 274.7 ± 3.27 0.374 ± 0.012 20.71 ± 1.04 60.19 68.42
F4 2 1 2 3 176.2 ± 1.82 0.275 ± 0.011 -34.0 ± 0.84 69.73 73.56
F5 2 2 3 1 209.4 ± 2.48 0.496 ± 0.032 20.14 ± 0.86 59.37 71.97
F6 2 3 1 2 215.8 ± 3.23 0.472 ± 0.061 -23.94 ± 1.03 61.19 71.38
F7 3 1 3 2 374.3 ± 4.17 0.561 ± 0.005 -23.21 ± 1.05 58.21 52.73
F8 3 2 1 3 327.9 ± 3.20 0.673 ± 0.083 -25.25 ± 0.95 54.80 36.69
F9 3 3 2 1 319.2 ± 4.15 0.712 ± 0.023 -24.69 ± 1.10 54.96 38.14
TABLE IX - Evaluation of ERY loaded SLN gel 
Clarity Mean pH ± S.D. (n=3) Homogenity
Mean Viscosity 
(Pa.s) ± S.D. (n=3)
Mean spreadability 
(gcm/sec) ± S.D. (n=3)
Mean Extrudability 
(gm) ± S.D. (n=3)
++ 6.5 ± 0.34 Good 9563 ± 7.48 19.51 ± 0.71 231 ± 4.65
FIGURE 1 - Particle size of optimized formulation (F4).
FIGURE 2 - In vitro release profile of developed SLNs.
FIGURE 3 - In vitro release profile of developed Plain and SLN 
loaded gel.
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profile (i.e. decrease of drug release with time due to 
increased diffusion path). This inherent limitation leads 
to first order release kinetic.
In our study, the formulation was designed for the 
controlled release of ERY, which was evaluated by in 
vitro drug release. To study the release kinetic of the drug, 
the result of the in vitro drug release studies were plotted 
with various kinetic models like zero order, first order, 
Kosermeyer and Peppas equation, and Higuchi’s kinetics 
model. The regression values for the models used for ERY-
SLN formulations are mentioned in Table X.
The result of the in vitro release study of SLN gel 
followed Higuchi kinetics (R2 =0.981). This correlates with 
the mechanism of drug release from a transdermal system. 
The Higuichi model was developed to depict the release 
of low soluble drugs when incorporated in semisolid and 
solid matrices (Bisht et al., 2017).
In vitro antimicrobial activity
A comparative evaluation of zone of inhibition 
of the prepared ERY SLN-loaded gel and ERY plain 
gel is mentioned in Figure 4. The zone of inhibiton of 
SLN-based gel was significantly higher as compared to 
plain gel. ERY-loaded SLNs gel can act as an effective 
therapeutic modality for treating acne by a decrease dose 
and frequency as well as improved patient compliance.
CONCLUSION
The ERY-loaded SLN gel was successfully 
incorporated into carbopol gel for topical delivery with 
a sustained release of drug. Carbopol 940 (2%w/v) gel 
was used as a hydrogel base with good spreadability and 
extrudability with compatible pH. The in vitro release 
profile of erythromycin-loaded SLN gel showed a 
sustained pattern of drug delivery, and thus it enhances 
antimicrobial activity after 30 hours when compared 
with ERY plain gel. The obtained results suggest that the 
developed formulation benefits from its nano size and 
promises better therapeutic efficacy. ERY SNL-loaded gel 
can therefore be a good replacement for the conventional 
formulation with benefits of decreased dose and dosing 
frequency as well as improved patient compliance.
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